Literature DB >> 23433138

Epithelioid PEComa (epithelioid angiomyolipoma) of the kidney: a rare tumor subtype for patients presenting with an enhancing renal mass.

Adam B Shrewsberry1, Gabriel L Sica, Adeboye O Osunkoya, Daniel J Canter.   

Abstract

Epithelioid angiomyolipomas, or perivascular epithelioid cell tumors (epithelioid PEComas) of the kidney, are histologically related to renal angiomyolipomas (AMLs). However, in contrast to typical AMLs, this rare tumor can exhibit an aggressive clinical course with approximately 50% of reported cases demonstrating disease progression. In this report, we present a case of a 24-year-old female with a history of stone disease who was incidentally found to have a 9.0 cm right renal mass that was difficult to characterize radiographically preoperatively. The patient underwent a right radical nephrectomy, and pathology revealed a renal epithelioid PEComa.

Entities:  

Mesh:

Year:  2013        PMID: 23433138

Source DB:  PubMed          Journal:  Can J Urol        ISSN: 1195-9479            Impact factor:   1.344


  4 in total

1.  Pigmented perivascular epithelioid cell tumor (PEComa) arising from kidney: A case report.

Authors:  Hexi Du; Jun Zhou; Lingfan Xu; Cheng Yang; Li Zhang; Chaozhao Liang
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

2.  Retroperitoneal PEComa: Case report and review of literature.

Authors:  Eric Singer; Susanna Yau; Michael Johnson
Journal:  Urol Case Rep       Date:  2018-03-31

3.  Calcified, minimally fat-contained angiomyolipoma clinically indistinguishable from a renal cell carcinoma.

Authors:  Chin-Li Chen; Shou-Hung Tang; Sheng-Tang Wu; En Meng; Chih-Wei Tsao; Guang-Huan Sun; Dah-Shyong Yu; Sun-Yran Chang; Tai-Lung Cha
Journal:  BMC Nephrol       Date:  2013-07-22       Impact factor: 2.388

Review 4.  Hepatic perivascular epithelioid cell tumor treated by transarterial embolization plus radiofrequency ablation: A case report and literature review.

Authors:  Haitao Guan; Yinghua Zou; Yongxing Lv; Chao Wang
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.